This biotechnology company got it's start California. Watch 'Behind the Label' TheStreet's new video series to learn more.
Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.
The cancer drugmaker post narrower-than-expected losses for the quarter and strong revenue growth.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.